New clarity for managing statin intolerance in diabetes
- PMID: 38061374
- DOI: 10.1016/S2213-8587(23)00352-2
New clarity for managing statin intolerance in diabetes
Conflict of interest statement
I have served on advisory boards for Acasti, Akcea-Ionis, Amgen, Arrowhead, HLS Therapeutics, Novartis, Pfizer, Sanofi, Regeneron, and UltraGenyx; and have received honoraria for continuing medical education talks from Amgen, HLS Therapeutics, and Novartis.
Comment on
-
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.Lancet Diabetes Endocrinol. 2024 Jan;12(1):19-28. doi: 10.1016/S2213-8587(23)00316-9. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061370 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
